Table 3.
Clinical course and outcomes of GI toxicity, n = 193
| Bortezomib N = 114 |
Carfilzomib N = 55 |
Ixazomib N = 24 |
|
|---|---|---|---|
| Characteristic | No. (%) | No. (%) | No. (%) |
| Symptom duration, days, median (IQR) | 12 (6–30) | 10 (5–32) | 21.5 (4.5–339.5) |
| Endoscopy performed | 11 (9.6%) | 4 (7.3%) | 2 (8.3%) |
| Location of GI toxicity | |||
| Upper GI | 0 (0%) | 1 (50.0%) | – |
| Small intestine | 3 (100%) | 0 (0%) | – |
| Colon | 0 (0%) | 1 (50.0%) | – |
| Gross findings | – | ||
| Normal | 8 (72.7%) | 1 (25.0%) | 2 (100%) |
| Non-ulcerous inflammation | 1 (9.1%) | 2 (50.0%) | 0 (0%) |
| Ulcerous inflammation | 2 (18.2%) | 1 (25.0%) | 0 (0%) |
| High-risk features present | 0 (0%)a | 2 (100%)a | – |
| Histologic findings | |||
| Normal | 9 (90.0%)a | 1 (33.3%)a | – |
| Acute inflammation | 1 (10.0%) | 1 (33.3%) | – |
| Chronic inflammation | 0 (0.0%) | 1 (33.3%) | – |
| Treatment for GI toxicity | |||
| No treatment | 19 (16.7%) | 12 (21.8%) | 5 (20.8%) |
| Supportive treatment | 95 (83.3%) | 43 (78.2%) | 19 (79.2%) |
| Duration of treatment, days, median (IQR) | 12 (7–32) | 11 (6–41) | 57 (4–602) |
| Hospitalization | 12 (10.5%) | 9 (16.4%) | 2 (8.3%) |
| Duration of hospitalization, days median (IQR) | 6.5 (3.5–9) | 5 (3–11) | 3 |
| Complications from the toxicity | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Response, n = 157 | 89 (93.7%) | 39 (90.7%) | 16 (84.2%) |
| Recurrence | 40 (35.1%) | 25 (45.5%) | 6 (25.0%) |
| Mortality | 51 (44.7%) | 31 (56.4%) | 8 (33.3%) |
aThese two groups differed significantly at the p < 0.05 level
GI, gastrointestinal; IQR, interquartile range